ProEncia Biotechnology, a fast-growing biopharma startup based in the Twin Cities, announced that it has closed significant pre-seed funding to advance its next-generation periodontal disease treatment platform. The funding will support the continued development, commercialization, and licensing of the company’s pipeline of novel, non-invasive periodontal care products designed for patients across all stages of periodontal disease severity.
Founded in 2022, ProEncia Biotechnology is focused on creating easy-to-use, non-toxic, and non-invasive oral care solutions targeting conditions including gingivitis and periodontitis. The company’s treatments are based on patent-pending technology and include multiple prophylactic and therapeutic products.
As part of the announcement, ProEncia also confirmed that the United States Patent and Trademark Office officially incorporated its provisional patent application titled “Compositions and Method for Prophylactic, Symptomatic, Therapeutic, and Cosmetic Periodontal Care” into a non-provisional PCT International application and entered it into the federal patent filing system.
According to the company, periodontal disease impacts more than one billion people globally and over 100 million people in the United States alone. The condition involves chronic inflammation and damage to the gums, ligaments, and bone supporting the teeth, and has increasingly been associated with broader health concerns including Alzheimer’s disease, dementia, heart disease, lung disease, immune system compromise, and worse COVID outcomes.
ProEncia Biotechnology was co-founded with the scientific and clinical leadership of Dr. Tarun Ghosh and Dr. Thomas Hoover.
KEY QUOTES:
“According to the World Health Organization, more than one billion people globally, and more than 100 million people in the U.S., suffer from periodontal disease. There’s an urgent need for innovation to resolve this epidemic and bring safe, effective solutions to lifelong sufferers of this condition.”
Tapos Ghosh, CEO And Co-Founder, ProEncia Biotechnology
“The commercial demand for a new approach to periodontal treatment is enormous. The ProEncia team is committed to advancing its groundbreaking treatment and expanding care options for periodontal disease patients.”
Austin Loeb, COO And Co-Founder, ProEncia Biotechnology
